Track Vir Biotechnology, Inc. — Monitor price, dividends, and performance in your free portfolio

Start Tracking Free

Vir Biotechnology, Inc. VIR · Stock Open Vir Biotechnology, Inc. in new tab

9.96 USD
EPS
-1.18
P/B
2.49
ROE
-21.84
Beta
1.74
Target Price
22.50 USD
Vir Biotechnology, Inc. logo

Vir Biotechnology, Inc.

🧾 Earnings Recap – Q1 2026

Shares dropped 11.4% following Q1 results as investors reacted negatively to cautious outlook and underwhelming financial updates despite clinical progress, signaling disappointment with the company's near-term prospects and margin pressures.

  • Collaboration with Astellas on VIR-5500 in prostate cancer advanced, with deal closure and joint clinical plans underway.
  • Phase I data showed a favorable safety profile for VIR-5500, notably no Grade 3 cytokine release syndrome and potential outpatient administration benefits.
  • Early signs of durable responses observed in heavily pretreated metastatic castration-resistant prostate cancer (MCRPC) patients, including some with liver metastases.
  • Dose escalation ongoing with expansion cohorts addressing both RLT-naive and post-RLT patient populations, plus early-line combination trials starting soon.
  • Financial commentary indicated concerns around guidance and margin trends, which were the likely drivers of the negative investor reaction despite clinical updates.
📅
Loading chart...
Key Metrics
Earnings dateFeb. 22, 2027
EPS-1.18
Book Value5.29
Price to Book2.49
Debt/Equity10.13
% Insiders6.496%
Growth
Revenue Growth195.83%
Estimates
Forward P/E-5.60
Forward EPS-2.35
Target Mean Price22.50

DCF valuation

Model fair value for Vir Biotechnology, Inc. (VIR)
Result
Sign in to run the valuation for VIR.
Assumptions
Growth– Capex– Tax– Terminal g– Cost of equity– Cost of debt–
Analyst price targets
8 analysts · consensus Strong buy · mean target 22.50 USD (low 17.00, high 30.00) · as of 10 Nov 2026
Low 17.00
Mean 22.50
High 30.00
Price 9.96
Published broker research as supplied by our market data feed, named by firm and dated; it does not identify individual analysts. Targets carry their last refresh date; rating changes can be a few days behind.

Vir Biotechnology, Inc. Logo Vir Biotechnology, Inc. Analysis (VIR)

United States Health Care Official Website Stock

Is Vir Biotechnology, Inc. a good investment? Vir Biotechnology, Inc. (VIR) is currently trading at 9.96 USD. Market analysts have a consensus price target of 22.50 USD. This suggests a potential upside from current levels.

Earnings Schedule: Vir Biotechnology, Inc. is expected to release its next earnings report on Feb. 22, 2027. The market consensus estimate for Forward EPS is -2.35.

Investor FAQ

Does Vir Biotechnology, Inc. pay a dividend?

No, it does not currently pay a dividend.

What asset class is Vir Biotechnology, Inc.?

Vir Biotechnology, Inc. is classified as a Stock. You can compare it against its peer in the "Related Symbols" list.

When is the next earnings date?

The next earnings date is projected to be Feb. 22, 2027. The company currently has a trailing EPS of -1.18.

Company Profile

Vir Biotechnology, Inc., a clinical-stage biopharmaceutical company, discovers and develops therapeutic products to treat and prevent serious infectious diseases in the United States and internationally. Its clinical development pipeline consists of product investigational therapies targeting hepatitis delta virus (HDV) and other solid tumors. The company's preclinical candidates include those targeting influenza A and B antibodies and antibody drug conjugates, and coronavirus monoclonal antibodies; and PRO-XTEN, a dual-masked TCEs targeting variety of solid tumors. It has grant collaboration and license agreement with Astellas; license agreement with Norgine for the treatment of CHD; amended and restated letter agreement with the Gates Foundation; an option and license agreement with Brii Biosciences Limited; a collaboration and license agreement with Alnylam Pharmaceuticals, Inc.; license agreement with the Institute for Research in Biomedicine; a license agreement with The Rockefeller University; license agreements with Xencor; and a collaborative research agreement with GlaxoSmithKline Biologicals S.A. Vir Biotechnology, Inc. was incorporated in 2016 and is headquartered in San Francisco, California.

Exchange Ticker
NMS (United States) VIR
Trades
No dividend information available for this instrument.
Explore Premium Features

Unlock detailed news and exclusive insights with our Premium subscription.

See Pricing Plans

Fundamentals

Under Construction

This feature will be available soon. Stay tuned!

Follow us on Twitter for updates: @allinvestview

Check out our Roadmap for upcoming features.

Community Discussion